A new study out calls into question whether Merck’s Gardasil cost effective. The study by Jane Kim and Sue Goldie of the Harvard School of Public Health relies on an analysis of “quality-adjusted life years.”
And they just might be right. Then again, when relying on population-level analysis like this, there’s almost no therapy will prove to be cost effective on a population level.
But the individual level is a whole different story. Do we deny the therapy to thousands of women who will develop cervical cancer this year? Are we willing to accept the deaths of thousands of women because it is not “cost effective?"
Relying on population-level cost analysis ignores the very real patients who suffer from these diseases.